B-type natriuretic peptide levels and its correlation with left ventricular functions and heart failure in patients of acute coronary syndromes
DOI:
https://doi.org/10.18203/2320-6012.ijrms20211360Keywords:
BNP, ACS, STEMI, NSTEMI, UA, CHF, LVESV, LVEDV, LVEF, ECGAbstract
Background: This study was designed to measure levels of B-type natriuretic peptide (BNP) across entire spectrum of acute coronary syndrome (ACS) and to find its correlation with left ventricular functions and heart failure.
Methods: We measured BNP levels at baseline in 100 consecutive patients between 24-96 hours after the onset of ischemic symptoms in patients of ACS. Echocardiography was performed in all patients between day 2-5 after the index diagnosis and stabilizing the patients.
Results: The BNP levels were raised across the entire spectrum of ACS, with levels (>80 pg/ml) in 32.2% of patients with ST segment-elevation myocardial infarction (STEMI), in 24% with non-ST segment-elevation myocardial infarction (NSTEMI), and in 16.6% with unstable angina (UA) respectively. High BNP levels were associated with greater increase in LV end-systolic volumes (r=+0.545, p<0.001) (LVESV) and end-diastolic volumes (LVEDV) (r=+0.336, p<0.001). There was a negative correlation between BNP levels and left ventricular ejection fraction (LVEF) (r=-0.394, p<0.002). BNP levels were significantly raised (156.0±45.1 vs 57.7±18.3 pg/ml, p<0.02) in patients developing symptomatic clinical heart failure, irrespective of LVEF ≤40%.
Conclusions: Integrated use of echocardiography and BNP levels provide powerful incremental assessment of cardiac functions, clinical status, and outcome across the entire spectrum of acute coronary syndromes (ACS). Increased BNP levels are associated with progressive ventricular dilatation, LV-dysfunction, development of clinical heart failure and is associated with poor prognosis in patients of ACS.
Metrics
References
Wiese S, Breyer T, Dragu A. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 2000;102:3074-9.
Yasue H, Yoshimura M, Sumida H. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
Yoshimura M, Yasue H, Okumura K. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464-9.
Homa N, Itoh H, Shirakami G. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995;92:1558-64.
Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J. 1998;135:914-23.
Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart. 1996;76:232-7.
Maisel AS, Koon J, Krishnaswamy P. utility of B-type natriuretic peptide as a rapid, point of care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am heart J. 2001;141:367-74.
Nagaya N, Nishikimi T, Goto Y. plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodelling after acute myocardial infarction. Am Heart J. 1998;135:21-8.
Richard AM, Nicholls MG, Ttandle TG. plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neuroharmonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921-9.
Omland T, Aakvaag A, Bonarjee VV. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963-9.
De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS et al. The prognostic value of B-type natriureteric peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-21.
Morrow DA, De Lemos JA, Sabastine MS. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;41:1264-72.
Mega JL, Marrow DA. B-type natriuretic peptide at presentation and prognosis in patients with ST-elevation myocardial infarction. An ENTIRE-TIMI-23 sub-study. J Am Coll Cardiol. 2004;44:335-9.
Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;85:334-40.
Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993;341:1109-13.
Talwar S, Squire IB, Downie PF. Profile of plasma N-terminal pro-BNP following acute myocardial infarction: correlation with left ventricular systolic dysfunction. Eur Heart J. 2000;21:1514-21.
Morita E, Yasue H, Yoshimura M. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88:82-91.
Dao Q, Krishnaswamy P, Kazanegra R. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379-85.
Richards AM, Nicholls MG. plasma N terminal pro-brain natriuretic peptide and adrenomedulin: new neurohormonal predictors of left ventricular functions and prognosis after myocardial infarction. Circulation. 1988;97:1921-7.
Ho KK, Anderson KM. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-15 .
Gunes Y, Okcun B, Kavlak E, Erbas C, Karcier S. Value of brain natriuretic peptide after acute myocardial infarction. Anadolu Kardiyol Derg. 2008;8:182-7.
Downloads
Published
How to Cite
Issue
Section
